Literature DB >> 25325831

A meta-analysis of the correlation between the HLA-DRB1*03 allele and chronic hepatitis B in the Han Chinese population.

Feng Gao1, Yang Zhang, Li-Kun Wang, Yong-Li Wei, Jing-Wei Wang, Cheng-Bao Wang, Qiang Li.   

Abstract

OBJECTIVE: This study sought to use a meta-analysis approach to comprehensively evaluate correlations between the human leukocyte antigen-DR beta 1 (HLA-DRB1)*03 allele and chronic hepatitis B (CHB) in the Han Chinese population.
METHODS: The China Biomedical Literature database (CBMdisc), the Chongqing VIP database (VIP), and the PubMed database were searched. Using the inclusion and exclusion criteria of this study, all relevant case-control studies retrieved in these searches that satisfied the conditions of this investigation were collected. Review Manager (RevMan) 5.2 software was used to conduct a meta-analysis on the results of these studies.
RESULTS: There were 9 publications that satisfied the inclusion criteria. These publications included a total of 970 cases in the CHB group and 1185 cases in the normal control group. Egger's test revealed no significant publication bias. A comprehensive analysis indicated that the pooled odds ratio (OR) value was 1.94 with a 95% confidence interval (CI) of 1.23-3.06 (Z=2.84, p=0.004); these findings suggested that in the Han Chinese population, the HLA-DRB1*03 allele is a susceptibility allele related to the occurrence of CHB.
CONCLUSION: There is a statistically significant correlation between the HLA-DRB1*03 allele and the occurrence of CHB in the Han Chinese population, and the HLA-DRB1*03 allele may be a susceptibility allele for this disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25325831     DOI: 10.1089/gtmb.2014.0096

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  1 in total

1.  Relationship between HLA-DRB1 allele polymorphisms and familial aggregations of hepatocellular carcinoma.

Authors:  S Ma; J Wu; J Wu; Y Wei; L Zhang; Q Ning; D Hu
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.